Posters

Clinical experience with the use of the first commercially available amniotic membrane insert in the UK and Ireland

Poster Details

First Author: L.Khoo UK

Co Author(s):    S. Srinivasan   M. Adams   S. Hamada   G. Willams   T. Fulcher        

Abstract Details

Purpose:

To report the real world clinical experience with the use of the first commercially available amniotic membrane insert (AMI) in the UK and Ireland for various ocular surface disorders

Setting:

Multiple clinical practises across the UK and Republic of Ireland

Methods:

Prospective, interventional case series. 15 adults (6 males and 9 females) with persistent corneal epithelial defects (PED) not responding to traditional treatment strategies that later underwent AMI were included. This cohort comprised of neurotrophic keratitis (n = 6) PED secondary to infectious keratitis (n=3), chemical injury (n =1), epithelial defect secondary to superficial keratectomy (n =2) peripheral ulcerative keratitis secondary to rheumatoid arthritis (n=1), sjogrens syndrome (n=1) limbal stem cell deficiency (n=1).

Results:

The AMI was easy to insert with no complications. The mean time of PED prior to AMI was 49 days. The mean time for complete reepithelisation following AMI was 29 days. 


Conclusions:

The first commercially available amniotic membrane insert seems to be an effective out patient treatment option in managing persistent epithelial defects of the cornea of varying etiology.

Financial Disclosure:

None